CDC recommendations
UPDATED OCTOBER 2024
CAPVAXIVE is a single-dose PCV recommended by the CDC for1
- Adults 50+
- Vaccine-naïve or vaccination history is unknown (lowered from 65+)
- Adults 19-49
- With certain chronic medical conditions or other behavioral risk factors who are vaccine-naïve or vaccination history is unknown
- Diabetes, renal disorders, chronic heart disease, chronic liver disease, or chronic lung disease, or other behavioral risk factors (eg, smoking or alcoholism)
- Previously Vaccinated Adults
- For Adults 19+
- Previously vaccinated with PCV13 only or PPSV23 only, ≥1 year prior at any age
- Previously vaccinated but have not completed a recommended seriesa
- For Adults 65+
- As a supplemental dose for those previously vaccinated with PCV13 and PPSV23*
*Routine if PCV13 was administered at any age and PPSV23 was administered before age 65 with the last pneumococcal vaccine being at least 5 years prior. Shared clinical decision-making if PCV13 was administered at any age and PPSV23 was administered at or after the age of 65 and the last pneumococcal vaccine was at least 5 years prior.1
aPatients are eligible to receive CAPVAXIVE if they only received PCV13 or PPSV23 ≥1 year ago or if last dose of PPSV23 was completed ≥5 years ago where PCV13 and PPSV23 were both received.1
Share with health care professionals
CDC, Centers for Disease Control and Prevention; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
Reference:
- Kobayashi M, Leidner AJ, Gierke R, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8. doi:10.15585/mmwr.mm7401a1